Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of BG-71332 in Healthy Adults
NCT07141511Phase 1Completed
- Sponsor
- BeOne Medicines
- Start
- Sep 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of zanubrutinib + sonrotoclax, sponsored by BeOne Medicines. Primary endpoints: Area under the plasma concentration-time curve from time 0 extrapolated to infinity for zanubrutinib, Area under the plasma concentration-time curve from time 0 extrapolated to infinity for sonrotoclax and 4 more. Started Sep 2025; status: completed.
02
Drugs
zanubrutinib + sonrotoclax
Beyond the preview
Go deeper on NCT07141511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07141511.